Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study

References

• Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76. doi:10.1016/j.ijsu.2020.02.034
   PubMed Web of Science ®Google Scholar
• Juul S, Nielsen N, Bentzer P, et al. Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). Syst Rev. 2020;9(1):108. doi:10.1186/s13643-020-01371-0
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):1371. doi:10.3390/jcm9051371
   Web of Science ®Google Scholar
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi:10.1111/jth.14768
   PubMed Web of Science ®Google Scholar
• Scudiero F, Silverio A, Di Maio M, et al. Cov-IT network. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021;198:34–39. doi:10.1016/j.thromres.2020.11.017
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145–7.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Bertinato EM, Birocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020.
   Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–73.
   PubMed Web of Science ®Google Scholar
• Shastri MD, Stewart N, Horne J, et al. In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of Enoxaparin. PLoS One. 2015;10(5):e0126763. doi:10.1371/journal.pone.0126763
   Web of Science ®Google Scholar
• Di Micco P, Di Micco G, Russo V, et al. Blood targets of adjuvant drugs against COVID19. J Blood Med. 2020;11:237–241. doi:10.2147/JBM.S256121
   Web of Science ®Google Scholar
• Tiwari V, Beer JC, Sankaranarayanan NV, Swanson-Mungerson M, Desai UR. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov Today. 2020;25(8):1535–1544. doi:10.1016/j.drudis.2020.06.017
   PubMed Web of Science ®Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Fondaparinux use in patients with COVID-19: a preliminary multicenter real-world experience. J Cardiovasc Pharmacol. 2020;76(4):369–371. doi:10.1097/FJC.0000000000000893
   PubMed Web of Science ®Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Thromboprophylaxis with fondaparinux versus enoxaparin in hospitalized covid-19 patients: a multicenter Italian observational study. Front Med (Lausanne). 2020;7. doi:10.3389/fmed.2020.569567
   Web of Science ®Google Scholar
• Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J Thromb Haemost. 2020;18(10):2629–2635. doi:10.1111/jth.15022
   PubMed Web of Science ®Google Scholar
• Raith EP, Udy AA, Bailey M, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit.. JAMA. 2017;317(3):290–300. doi:10.1001/jama.2016.20328
   PubMed Web of Science ®Google Scholar
• Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32–67. doi:10.1007/s11239-015-1317-0
   PubMed Web of Science ®Google Scholar
• Lobo JL, Zorrilla V, Aizpuru F, et al. RIETE investigators. D-dimer levels and 15-day outcome in acute pulmonary embolism. Findings from the RIETE registry. J Thromb Haemost. 2009;7(11):1795–1801. doi:10.1111/j.1538-7836.2009.03576.x
   Web of Science ®Google Scholar
• Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. Neth J Med. 2016;74(10):443–448.
   PubMed Web of Science ®Google Scholar
• Di Micco P, D’Uva M, Strina I, et al. The role of D-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia induced sterility. J Transl Med. 2004;2(1):38. doi:10.1186/1479-5876-2-38
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10233):1340. doi:10.1016/S0140-6736(20)30869-2
   PubMed Web of Science ®Google Scholar
• Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–136.e4. doi:10.1016/j.jaci.2020.05.008
   PubMed Web of Science ®Google Scholar
• Beinrohr L, Murray-Rust TA, Dyksterhuis L, et al. Serpins and the complement system. Methods Enzymol. 2011;499:55–75.
   Web of Science ®Google Scholar
• Vicci H, Eblen-Zajjur A, López M, Crespo G, Navarro M. Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model. Inflammopharmacology. 2019;27(3):521–529. doi:10.1007/s10787-018-0444-6
   Web of Science ®Google Scholar
• Shi C, Wang C, Wang H, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study [published online ahead of print, 2020 Sep 3]. Clin Transl Sci. 2020;13(6):1087–1095. doi:10.1111/cts.12880
   Web of Science ®Google Scholar
• Marietta M, Vandelli P, Mighali P, et al. Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials. 2020;21(1):574.
   PubMed Web of Science ®Google Scholar
• Paschoa AF. Heparin: 100 years of pleiotropic effects. J Thromb Thrombolysis. 2016;41(4):636–643. doi:10.1007/s11239-015-1261-z
   Web of Science ®Google Scholar
• Keshari RS, Silasi R, Popescu NI, et al. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost. 2020;18(1):180–190. doi:10.1111/jth.14642
   PubMed Web of Science ®Google Scholar
• Iba T, Okamoto K, Ohike T, et al. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. J Trauma Acute Care Surg. 2012;72(1):177–182. doi:10.1097/TA.0b013e31821a83f0
   Web of Science ®Google Scholar
• Tan KT, Lip GY. Fondaparinux. Curr Pharm Des. 2005;11(4):415–419. doi:10.2174/1381612053382089
   Web of Science ®Google Scholar
• Di Micco P, Russo V, Lodigiani C. Venous thromboembolism and its association with COVID-19: still an open debate. Medicina (Kaunas). 2020;56(10):506. doi:10.3390/medicina56100506
   Web of Science ®Google Scholar